CN105163728B - 包含蜂胶提取物的治疗性组合物和其用途 - Google Patents

包含蜂胶提取物的治疗性组合物和其用途 Download PDF

Info

Publication number
CN105163728B
CN105163728B CN201480022371.8A CN201480022371A CN105163728B CN 105163728 B CN105163728 B CN 105163728B CN 201480022371 A CN201480022371 A CN 201480022371A CN 105163728 B CN105163728 B CN 105163728B
Authority
CN
China
Prior art keywords
alkoxy
propolis
hydroxyl
gastrointestinal cancer
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480022371.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105163728A (zh
Inventor
K·保罗
O·卡奇普尔
K·米切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Manuka Health New Zealand Ltd
Original Assignee
Manuka Health New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manuka Health New Zealand Ltd filed Critical Manuka Health New Zealand Ltd
Publication of CN105163728A publication Critical patent/CN105163728A/zh
Application granted granted Critical
Publication of CN105163728B publication Critical patent/CN105163728B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480022371.8A 2013-04-05 2014-04-07 包含蜂胶提取物的治疗性组合物和其用途 Active CN105163728B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ609106 2013-04-05
NZ60910613 2013-04-05
PCT/NZ2014/000059 WO2014163512A1 (en) 2013-04-05 2014-04-07 Therapeutic compositions comprising extracts of propolis and uses thereof

Publications (2)

Publication Number Publication Date
CN105163728A CN105163728A (zh) 2015-12-16
CN105163728B true CN105163728B (zh) 2018-10-02

Family

ID=51658695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480022371.8A Active CN105163728B (zh) 2013-04-05 2014-04-07 包含蜂胶提取物的治疗性组合物和其用途

Country Status (7)

Country Link
US (1) US20160030364A1 (enExample)
EP (1) EP2981254B1 (enExample)
JP (1) JP6444984B2 (enExample)
CN (1) CN105163728B (enExample)
AU (1) AU2014250138B2 (enExample)
TW (1) TW201517901A (enExample)
WO (1) WO2014163512A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983681B1 (en) 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
TW201609113A (zh) * 2014-07-18 2016-03-16 歐文 約翰 蓋奇波 治療組合物及其用途
RU2568876C1 (ru) * 2015-02-11 2015-11-20 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ определения оксима пиностробина в плазме крови
JP2019515943A (ja) * 2016-03-24 2019-06-13 マヌカ ヘルス ニュージーランド リミテッド 治療用組成物およびその使用
CN106913873A (zh) * 2017-04-26 2017-07-04 中国药科大学 巴西绿蜂胶在制备pdt抗肿瘤的协同增效药物中的应用
WO2020086830A2 (en) * 2018-10-26 2020-04-30 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
US20220370385A1 (en) * 2019-09-17 2022-11-24 Enzene Biosciences Ltd. Compositions for use in inhibiting src kinase and treating and preventing associated disorders
CN116492324A (zh) * 2023-01-04 2023-07-28 河南科技大学第一附属医院 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022740A2 (en) * 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO2002047615A2 (en) * 2000-12-13 2002-06-20 University Of Rochester Oral compositions and use thereof
US6689811B2 (en) * 2001-04-20 2004-02-10 Wake Forest University Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers
JP2003119169A (ja) * 2001-07-30 2003-04-23 Shigetoshi Kadota 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
KR100968367B1 (ko) * 2006-10-02 2010-07-06 재단법인서울대학교산학협력재단 카페인산 유도체 및 이를 유효성분으로 포함하는 조성물
CN101502506B (zh) * 2009-02-24 2011-08-17 连晓媛 咖啡酸3,4-二羟基苯乙酯的医药用途
WO2011156889A1 (en) * 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
CN101875648B (zh) * 2010-07-12 2012-12-12 马灵媛 一种从药用植物中提取纯化球松素的方法及其药物制剂与应用
WO2013078371A2 (en) * 2011-11-22 2013-05-30 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
CN102949384A (zh) * 2012-10-29 2013-03-06 浙江大学 咖啡酸3，4-二羟基苯乙酯在制备抗肿瘤药物中的应用
CN104016862A (zh) * 2013-02-28 2014-09-03 北京大学 咖啡酸苯乙酯酚羟基保护衍生物的制备及其作为神经保护剂和抗肿瘤药物的应用
EP2983681B1 (en) * 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022740A2 (en) * 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cytotoxicity of Constituents from Mexican Propolis Against a Panel of Six Different Cancer Cell Lines;Feng Li et al.;《Natural Product Communications》;20100706;第5卷(第10期);第1603页 *
Inhibitory Effect of Caffeic Acid Esters on Azoxymethane-induced Biochemical Changes and Aberrant Crypt Foci Formation in Rat Colon;Chinthalapally Y. Rao et al.;《CANCER RESEARCH》;19930915;摘要以及第4183页 *

Also Published As

Publication number Publication date
EP2981254A1 (en) 2016-02-10
EP2981254A4 (en) 2017-01-11
CN105163728A (zh) 2015-12-16
AU2014250138B2 (en) 2018-11-15
AU2014250138A1 (en) 2015-11-19
HK1215859A1 (zh) 2016-09-23
EP2981254B1 (en) 2018-10-10
TW201517901A (zh) 2015-05-16
WO2014163512A1 (en) 2014-10-09
JP2016515615A (ja) 2016-05-30
JP6444984B2 (ja) 2018-12-26
US20160030364A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CN105163728B (zh) 包含蜂胶提取物的治疗性组合物和其用途
US10420804B2 (en) Therapeutic compositions and uses thereof
AU2023202398B2 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
AU2023201100B2 (en) Therapeutic compositions and uses thereof
US9820963B2 (en) Composition containing lignan compound as active ingredient for preventing or treating cancer
TW201733619A (zh) 肌肽二肽酶阻礙用組成物
KR101418164B1 (ko) 자외선을 처리한 벼 추출물을 유효성분으로 포함하는 대장암 예방 또는 치료용 약학적 조성물
HK1215859B (en) Therapeutic compositions comprising extracts of propolis and uses thereof
TW200522973A (en) Neutralization agent of vacuolization toxin
HK1220920B (zh) 治疗性组合物和其用途
HK1261075A1 (en) Therapeutic compositions and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215859

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant